Comparative Pharmacology
Head-to-head clinical analysis: AIMOVIG versus QULIPTA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AIMOVIG versus QULIPTA.
AIMOVIG vs QULIPTA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
AIMOVIG (erenumab) is a human monoclonal antibody that binds to the calcitonin gene-related peptide (CGRP) receptor and antagonizes CGRP receptor function. CGRP is a neuropeptide involved in the pathophysiology of migraine; its release leads to vasodilation and activation of pain pathways.
QULIPTA (atogepant) is a calcitonin gene-related peptide (CGRP) receptor antagonist. It competitively blocks the binding of CGRP to its receptor, thereby inhibiting CGRP-mediated vasodilation and pain transmission involved in migraine pathophysiology.
70 mg subcutaneously once monthly; some patients may benefit from 140 mg subcutaneously once monthly.
10 mg orally once daily
None Documented
None Documented
28 days (range 23-31 days) in healthy volunteers; supports monthly subcutaneous dosing.
Terminal elimination half-life is approximately 21 hours, supporting once-daily dosing.
Elimination via proteolytic catabolism; no renal or biliary excretion of intact antibody.
Approximately 60% of the dose is excreted in feces (as unchanged drug and metabolites) and 40% in urine (primarily as metabolites, with <1% unchanged).
Category C
Category C
CGRP Antagonist
CGRP Antagonist